[1]陆新虹,温玉洁,胡 欣,等.α-硫辛酸对2型糖尿病肾病患者 血清内脂素的影响研究[J].医学信息,2018,31(14):60-63.[doi:10.3969/j.issn.1006-1959.2018.14.019]
　LU Xin-hong,WEN Yu-jie,HU Xin,et al.Effect of α-lipoic Acid on Serum Visfatin in Patients with Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2018,31(14):60-63.[doi:10.3969/j.issn.1006-1959.2018.14.019]
点击复制

α-硫辛酸对2型糖尿病肾病患者 血清内脂素的影响研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年14期
页码:
60-63
栏目:
论著
出版日期:
2018-07-15

文章信息/Info

Title:
Effect of α-lipoic Acid on Serum Visfatin in Patients with Type 2 Diabetic Nephropathy
文章编号:
1006-1959（2018）14-0060-04
作者:
陆新虹1; 温玉洁1; 胡 欣1; 马小燕2
广西壮族自治区南溪山医院内分泌科1，检验科2，广西 桂林 541002
Author(s):
LU Xin-hong1; WEN Yu-jie1; HU Xin1; MA Xiao-yan2
Department of Endocrinology1,Department of Laboratory Medicine2,Nanxishan Hospital,Guangxi Zhuang Autonomous Region,Guilin 541002,Guangxi,China
关键词:
糖尿病肾病; α-硫辛酸; 内脂素; 尿蛋白排泄率
Keywords:
Key words：Diabetic nephropathy; α-lipoic acid; Visfatin; Urinary protein excretion rate
分类号:
R587.2
DOI:
10.3969/j.issn.1006-1959.2018.14.019
文献标志码:
A
摘要:
目的 探讨α-硫辛酸对2型糖尿病患者血清内脂素的影响。方法 选取2型糖尿病合并肾病患者90例，按照尿微量白蛋白/肌酐（尿ACR）分为微量蛋白尿硫辛酸治疗组（尿ACR 30~300 μg/mg）30例，微量蛋白尿常规治疗组30例，大量蛋白尿硫辛酸治疗组（尿ACR＞300 μg/mg）30例。常规治疗组给予降糖、降压治疗，硫辛酸治疗组分别在常规治疗基础上给予α-硫辛酸300 mg/d静脉滴注。疗程10 d。治疗前及疗程结束后测定所有参与者尿ACR及血清内脂素。结果 微量-常规组治疗后内脂素无改变（35.17±10.64 vs 33.28±9.51 pg/ml，P＞0.05），尿ACR无改变（59.5±29.4 vs 60.14±32.51μg/mg，P＞0.05）；微量-硫辛酸组治疗后内脂素下降（33.31±9.5 vs 28.76±10.79 pg/ml，P＜0.01），尿ACR无改变（62.09±35.1 vs 58.29±30.08 μg/mg，P＞0.05）；大量-硫辛酸组治疗后内脂素下降（65.7±17.0 vs 54.62±12.51 pg/ml，P＜0.01），尿ACR无改变（459.1±103.5 vs 443.61±109.44 μg/mg，P＞0.05）。结论 α-硫辛酸治疗可以减低糖尿病肾病患者血清内脂素水平，但短疗程（10 d）硫辛酸治疗不能减少尿蛋白排泄率。
Abstract:
Abstract：Objective To investigate the effect of α-lipoic acid on serum visfatin in patients with type 2 diabetes mellitus.Methods 90 patients with type 2 diabetes mellitus complicated with nephropathy were enrolled,according to urinary microalbumin/creatinine (urine ACR),30 cases of microalbuminuria treatment group(urine ACR 30~300μg/mg),30 cases of microalbuminurial treatment group, and a large number of proteinuria lipoic acid treatment group( Urinary ACR>300 μg/mg)in 30 cases.The conventional treatment group was given hypoglycemic and antihypertensive treatment,and the lipoic acid treatment group was given an intravenous infusion of α-lipoic acid 300 mg/d on the basis of conventional treatment.The course of treatment is 10 d.All participants were tested for urinary ACR and serum visfatin before and after treatment.Results There was no change in visfatin after treatment in the micro-routine group(35.17±10.64vs33.28±9.51pg/ml,P>0.05),and there was no change in urinary ACR(59.5±29.4vs60.14±32.51μg/mg,P>0.05);The visfatin decreased after treatment with the micro-lipoic acid group(33.31±9.5vs28.76±10.79pg/ml,P<0.01),and there was no change in urinary ACR(62.09±35.1vs 58.29±30.08 μg/mg,P>0.05);The visfatin decreased after treatment in the high-lipoic acid group(65.7±17.0 vs54.62±12.51pg/ml,P<0.01),and there was no change in urinary ACR(459.1±103.5vs443.61±109.44 μg/mg,P>0.05).Conclusion α-lipoic acid treatment can reduce serum visfatin levels in patients with diabetic nephropathy,but short-course(10 d)lipoic acid treatment can not reduce urinary protein excretion rate.

参考文献/References:

[1]Duran-Salgado MB,Rubio-Guerra AF.Diabetic nephropathy and inflammation[J].World J Diabetes,2014,5(3):393-398. [2]Ma X,An L,Wang Q.Changes in Serum Nampt Levels and Its Significances in Diabetic NephropathyPatients.The Potential Role of Nampt in T2DM with Diabetic Nephropathy[J].Endocr Metab Immune Disord Drug Targets,2017,17(2):114-124. [3]Wu XT,Yang Z,Ansari AR,et al.Visfatin regulates the production of lipopolysaccharide-induced inflammatory cytokines through p38 signaling in murine macrophages[J].Microb Pathog,2018(117):55-59. [4]Wu MH,Tsai CH,Huang YL,et al.VisfatinPromotes IL-6 and TNF-α Production in Human Synovial Fibroblasts by Repressing miR-199a-5p through ERK,p38 and JNK Signaling Pathways[J].Int J Mol Sci,2018,19(1):E190. [5]Kang YS,Song HK,Lee MH,et al.Visfatin is upregulated intype-2 diabetic rats and targets renal cells[J].Kidney Int,2010,78(2):170-181. [6]Tabassum A,Mahboob T.Role of peroxisome proliferator-activated receptor-gamma activation on visfatin,advanced glycation end products,and renal oxidativestress in obesity-induced type 2 diabetes mellitus[J].Hum Exp Toxicol,2018(1):960327118757588. [7]周宝尚.激活FXR下调visfatin对糖尿病肾病的作用及机制研究[D].第三军医大学,2017. [8]邵云,秦小霞,魏从真,等.α-硫辛酸对肥胖模型大鼠血清脂肪因子的影响[J].检验医学,2015,30(11):1147-1149.

相似文献/References:

[1]陈淑雯.肾衰宁联合科素亚治疗早期糖尿病肾病的临床观察[J].医学信息,2018,31(05):20.[doi:10.3969/j.issn.1006-1959.2018.05.007]
　CHEN Shu-wen.Clinical Observation on Early Diabetic Nephropathy Treated by Shenshuaining Combined with Kosu[J].Journal of Medical Information,2018,31(14):20.[doi:10.3969/j.issn.1006-1959.2018.05.007]
[2]何丽杰.中西医治疗糖尿病肾病的临床效果分析[J].医学信息,2018,31(10):149.[doi:10.3969/j.issn.1006-1959.2018.10.051]
　HE Li-jie.Clinical Effect Analysis of Diabetic Nephropathy Treated by Chinese and Western Medicine[J].Journal of Medical Information,2018,31(14):149.[doi:10.3969/j.issn.1006-1959.2018.10.051]
[3]贺 伟,高 峰.24 h尿微量白蛋白、血清胱抑素C水平与血清肌酐、尿素水平在2型糖尿病肾病早期诊断的意义[J].医学信息,2018,31(11):151.[doi:10.3969/j.issn.1006-1959.2018.11.049]
　HE Wei,GAO Feng.The Significance of 24 h Urinary Microalbumin,Serum Cystatin C and Serum Creatinine and Urea Levels in the Early Diagnosis of Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2018,31(14):151.[doi:10.3969/j.issn.1006-1959.2018.11.049]
[4]黄秋菊.胱抑素C及脂蛋白α在早期糖尿病肾病诊断中的价值研究[J].医学信息,2018,31(14):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
　HUANG Qiu-ju.The Value of Cystatin C and Lipoprotein α in the Diagnosis of Early Diabetic Nephropathy[J].Journal of Medical Information,2018,31(14):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
[5]肖学秀.益气活血汤联合西药治疗早期糖尿病肾病的临床观察[J].医学信息,2019,32(02):166.[doi:10.3969/j.issn.1006-1959.2019.02.051]
　XIAO Xue-xiu.Clinical Observation of Yiqi Huoxue Decoction Combined with Western Medicine in Treating Earlyn Diabetic Nephropathy[J].Journal of Medical Information,2019,32(14):166.[doi:10.3969/j.issn.1006-1959.2019.02.051]
[6]郑小鹏,辛 华.糖尿病肾病研究进展[J].医学信息,2018,31(16):26.[doi:10.3969/j.issn.1006-1959.2018.16.008]
　ZHENG Xiao-peng,XIN Hua.Progress in the Study of Diabetic Nephropathy[J].Journal of Medical Information,2018,31(14):26.[doi:10.3969/j.issn.1006-1959.2018.16.008]
[7]李志俊,王 利,王 浩.姜黄素改善糖尿病肾病的作用机制研究[J].医学信息,2018,31(24):35.[doi:10.3969/j.issn.1006-1959.2018.24.010]
　LI Zhi-jun,WANG Li,WANG Hao.Study on the Mechanism of Curcumin in Improving Diabetic Nephropathy[J].Journal of Medical Information,2018,31(14):35.[doi:10.3969/j.issn.1006-1959.2018.24.010]
[8]张国艳,张佳田,隋洪玉.糖尿病肾病大鼠动物模型建立及INF-α干预机制研究[J].医学信息,2019,32(05):101.[doi:10.3969/j.issn.1006-1959.2019.05.030]
　ZHANG Guo-yan,ZHANG Jia-tian,SUI Hong-yu.Establishment of Animal Model of Diabetic Nephropathy Rats and Study of INF-α Intervention Mechanism[J].Journal of Medical Information,2019,32(14):101.[doi:10.3969/j.issn.1006-1959.2019.05.030]
[9]吴怡琪,卢 文.皮肤AGEs荧光检测对糖尿病肾病的临床意义[J].医学信息,2019,32(06):101.[doi:10.3969/j.issn.1006-1959.2019.06.031]
　WU Yi-qi,LU Wen.Clinical Significance of Skin AGEs Fluorescence Detection in Diabetic Kidney Disease[J].Journal of Medical Information,2019,32(14):101.[doi:10.3969/j.issn.1006-1959.2019.06.031]
[10]王 然,佟成媛.糖尿病肾病患者尿微量白蛋白、免疫球蛋白G、转铁蛋白和视黄醇结合蛋白的检测及意义[J].医学信息,2019,32(07):175.[doi:10.3969/j.issn.1006-1959.2019.07.056]
　WANG Ran,TONG Cheng-yuan.Detection and Significance of Urinary Microalbumin,Immunoglobulin G,Transferrin and Retinol Binding Protein in Patients with Diabetic Nephropathy[J].Journal of Medical Information,2019,32(14):175.[doi:10.3969/j.issn.1006-1959.2019.07.056]

更新日期/Last Update: 2018-07-15